Celgene solid in 3Q, looks to Abraxane's potential in melanoma
This article was originally published in Scrip
Executive Summary
Celgene reported a 14% increase in net product sales for the third quarter of 2012 on 25 October as well as upbeat Phase III clinical trial results in metastatic melanoma for Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin bound) ahead of late-stage data in pancreatic cancer.